Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D92KUQ
|
|||
| Drug Name |
ARN-6039
|
|||
| Synonyms |
6-methoxy-5-morpholino-2-((3-(trifluoromethyl)pyridin-2-yl)methyl)-2,3-dihydro-1H-inden-1-one; 1675206-11-7; SCHEMBL16552820; COc1cc2C(=O)C(Cc3ncccc3C(F)(F)F)Cc2cc1N1CCOCC1
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40] | Phase 1 | [1] | |
| Company |
Arrien Pharmaceuticals; Boston Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H21F3N2O3
|
|||
| Canonical SMILES |
COC1=C(C=C2CC(C(=O)C2=C1)CC3=C(C=CC=N3)C(F)(F)F)N4CCOCC4
|
|||
| InChI |
1S/C21H21F3N2O3/c1-28-19-12-15-13(11-18(19)26-5-7-29-8-6-26)9-14(20(15)27)10-17-16(21(22,23)24)3-2-4-25-17/h2-4,11-12,14H,5-10H2,1H3
|
|||
| InChIKey |
CQSDLVKTQRLMJB-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nuclear receptor ROR-gamma (RORG) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03237832) A Phase 1 Study of ARN-6039 (ARN-6039). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Arrien Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.